Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort.
Zeinomar N, Phillips KA, Daly MB, Milne RL, Dite GS, MacInnis RJ, Liao Y, Kehm RD, Knight JA, Southey MC, Chung WK, Giles GG, McLachlan SA, Friedlander ML, Weideman PC, Glendon G, Nesci S; kConFab Investigators; Andrulis IL, Buys SS, John EM, Hopper JL, Terry MB. Zeinomar N, et al. Among authors: mclachlan sa. Int J Cancer. 2019 Jul 15;145(2):370-379. doi: 10.1002/ijc.32112. Epub 2019 Feb 20. Int J Cancer. 2019. PMID: 30725480 Free PMC article.
Cancer risk management practices of noncarriers within BRCA1/2 mutation positive families in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer.
Dawson SJ, Price MA, Jenkins MA, McKinley JM, Butow PN, McLachlan SA, Lindeman GJ, Weideman P, Friedlander ML, Hopper JL, Phillips KA. Dawson SJ, et al. Among authors: mclachlan sa. J Clin Oncol. 2008 Jan 10;26(2):225-32. doi: 10.1200/JCO.2007.11.0262. Epub 2007 Nov 26. J Clin Oncol. 2008. PMID: 18040054
Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).
Kiely BE, Jenkins MA, McKinley JM, Friedlander ML, Weideman P, Milne RL, McLachlan SA, Hopper JL, Phillips KA. Kiely BE, et al. Among authors: mclachlan sa. Breast Cancer Res Treat. 2010 Apr;120(3):715-23. doi: 10.1007/s10549-009-0497-8. Epub 2009 Aug 11. Breast Cancer Res Treat. 2010. PMID: 19669874
Prostate screening uptake in Australian BRCA1 and BRCA2 carriers.
McKinley JM, Weideman PC, Jenkins MA, Friedlander ML, Hopper JL, McLachlan SA, Lindeman GJ; Investigators KConFab; Phillips KA. McKinley JM, et al. Among authors: mclachlan sa. Hered Cancer Clin Pract. 2007 Sep 15;5(3):161-3. doi: 10.1186/1897-4287-5-3-161. Hered Cancer Clin Pract. 2007. PMID: 19725993 Free PMC article.
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
Phillips KA, Milne RL, Rookus MA, Daly MB, Antoniou AC, Peock S, Frost D, Easton DF, Ellis S, Friedlander ML, Buys SS, Andrieu N, Noguès C, Stoppa-Lyonnet D, Bonadona V, Pujol P, McLachlan SA, John EM, Hooning MJ, Seynaeve C, Tollenaar RA, Goldgar DE, Terry MB, Caldes T, Weideman PC, Andrulis IL, Singer CF, Birch K, Simard J, Southey MC, Olsson HL, Jakubowska A, Olah E, Gerdes AM, Foretova L, Hopper JL. Phillips KA, et al. Among authors: mclachlan sa. J Clin Oncol. 2013 Sep 1;31(25):3091-9. doi: 10.1200/JCO.2012.47.8313. Epub 2013 Aug 5. J Clin Oncol. 2013. PMID: 23918944 Free PMC article.
Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer.
Collins IM, Milne RL, McLachlan SA, Friedlander M, Hickey M, Weideman PC, Birch KE, Hopper JL, Phillips KA. Collins IM, et al. Among authors: mclachlan sa. J Clin Oncol. 2013 Nov 1;31(31):3920-5. doi: 10.1200/JCO.2013.49.3007. Epub 2013 Sep 30. J Clin Oncol. 2013. PMID: 24081944
152 results